Setting a new standard for the treatment of chronic inflammation. Press Releases Catch up on the latest news from Evommune. March 20, 2024 Evommune Announces Expanded Strategic Collaboration with Maruho to Develop and Commercialize MRGPRX2 Antagonist EVO756 in Greater China and Key Asian Countries January 18, 2024 Evommune Announces Initation of a Phase 1 Trial of its MRGPRX2 Antagonist for the Treatment of Chronic Spontaneous Urticaria November 28, 2023 Evommune and Accutar Biotechnology Announce AI Drug Discovery Collaboration September 27, 2023 Evommune Announces Strategic Collaboration with Maruho to Develop and Commercialize MRGPRX2 antagonist EVO756 in Japan June 28, 2023 Evommune Adds Additional Investment In Series B Financing And Bolsters Leadership Team April 26, 2023 Evommune Closes $50 Million Series B Financing to Advance Broad Pipeline of Therapies to Treat Chronic Inflammatory Diseases October 3, 2022 Evommune Announces Appointment of Dr. Jeegar Patel as Chief Scientific Officer June 27, 2022 Evommune Announces Appointment of Greg Moss as Chief Corporate Strategy and Legal Officer March 22, 2022 Evommune Announces Appointment of Kyle Carver as Chief Financial Officer November 16, 2021 Evommune to Present at the 2021 American College of Toxicology Annual Meeting and the Annual Dermatology Drug Development Summit for Inflammatory Diseases 12 We have a range of chronic inflammatory disease programs currently in development. See Our Pipeline